[Full Year 2024 Financial Results and Business Update](index=1&type=section&id=Full%20Year%202024%20Financial%20Results%20and%20Business%20Update) [Business Highlights](index=1&type=section&id=Business%20Highlights) The company advanced its mRNAi GOLD™ platform with strong clinical execution, prioritizing rare disease programs and extending its cash runway into 2027 by partnering zerlasiran - The company is strategically prioritizing investments in programs for rare conditions, such as **divesiran for Polycythemia Vera (PV)**[2](index=2&type=chunk) - The Phase 3 cardiovascular outcomes study for zerlasiran will only be initiated after securing a partner, a decision that **extends the company's cash runway into 2027**[2](index=2&type=chunk)[6](index=6&type=chunk) [Zerlasiran for Cardiovascular Disease](index=1&type=section&id=Zerlasiran%20for%20Cardiovascular%20Disease) The zerlasiran program received positive regulatory feedback for its Phase 3 design and is prepared for H1 2025, with initiation contingent on securing a partnership - Received **positive feedback on the Phase 3 study design** from major global regulatory bodies including the U.S. FDA, European EMA, and Japanese PMDA[4](index=4&type=chunk) - The program is on track to be **Phase 3 ready in H1 2025**, but the study's start is dependent on securing a partner[4](index=4&type=chunk) [Divesiran for Polycythemia Vera (PV)](index=1&type=section&id=Divesiran%20for%20Polycythemia%20Vera%20(PV)) The divesiran program is advancing with Phase 1 follow-up concluded and Phase 2 enrollment expected to complete by year-end 2025 - Follow-up has concluded in the SANRECO Phase 1 study, with **data presentations anticipated in 2025**[4](index=4&type=chunk) - **Full enrollment in the SANRECO Phase 2 study** is expected by the end of 2025[2](index=2&type=chunk)[4](index=4&type=chunk) [Other mRNAi GOLD™ Pipeline Updates](index=1&type=section&id=Other%20mRNAi%20GOLD%E2%84%A2%20Pipeline%20Updates) The company plans a Phase 1 study for SLN548, continues the SLN312 study, and has regained rights to three preclinical programs from Hansoh Pharma - A Phase 1 study of **SLN548**, a wholly-owned siRNA candidate for complement-mediated diseases, is planned for **H2 2025**[3](index=3&type=chunk) - The collaboration with Hansoh Pharma has ended, and **Silence has regained global rights** to all three associated preclinical programs[9](index=9&type=chunk) - A Phase 1 study of **SLN312**, which is licensed to AstraZeneca, is currently ongoing[9](index=9&type=chunk) [Financial Highlights and Guidance](index=2&type=section&id=Financial%20Highlights%20and%20Guidance) The company reported a strong cash position of $147.3 million, increased collaboration revenue, a narrowed net loss, and an extended cash runway into 2027 Key Financial Metrics for Year End 2024 | Metric | 2024 | 2023 | | :--- | :--- | :--- | | Cash, Cash Equivalents, and Short-term Investments | $147.3 million | $68.8 million | | Collaboration Revenue | $43.1 million | $30.9 million | | R&D Expenses | $67.9 million | $56.9 million | | G&A Expenses | $26.9 million | $26.2 million | | Net Loss | $45.3 million | $54.2 million | | Net Loss Per Share | $0.33 | $0.49 | - The company's projected **cash runway is now extended into 2027**[2](index=2&type=chunk)[6](index=6&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) The 2024 consolidated financial statements show increased revenue, a reduced net loss, and a significantly strengthened balance sheet with higher cash and lower liabilities [Consolidated Statements of Income (Loss)](index=5&type=section&id=Consolidated%20Statements%20of%20Income%20(Loss)) For fiscal year 2024, revenue increased to $43.3 million while the net loss improved to $45.3 million, or $0.33 per share Consolidated Statements of Income (Loss) (in thousands, except for loss per share) | | 2024 | 2023 | | :--- | :--- | :--- | | **Revenue** | **$ 43,258** | **$ 31,643** | | Gross profit | $ 31,448 | $ 18,776 | | Research and development costs | $ (67,883) | $ (56,937) | | General and administrative expenses | $ (26,884) | $ (26,222) | | Operating loss | $ (63,319) | $ (64,383) | | **Net Loss** | **$ (45,309)** | **$ (54,228)** | | **Loss per share (basic and diluted)** | **$ (0.33)** | **$ (0.49)** | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2024, the balance sheet reflects strong liquidity with total assets of $202.6 million and significantly reduced total liabilities Consolidated Balance Sheets (in thousands) | | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Current assets** | | | | Cash and cash equivalents | $ 121,330 | $ 68,789 | | Short-term investments | $ 26,004 | $ — | | **Total current assets** | **$ 187,366** | **$ 103,151** | | **Total assets** | **$ 202,635** | **$ 119,448** | | **Current liabilities** | | | | Total current liabilities | $ (16,822) | $ (22,336) | | **Total liabilities** | **$ (68,612)** | **$ (97,455)** | | **Total shareholders' equity** | **$ (134,023)** | **$ (21,993)** |

Shares of Silence Therapeutics (SLN) plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) or Lp(a), a key genetic risk factor for cardiovascular disease. The stock price drop is likely due to investors’ skepticism regarding the effectiveness of the candidate compared to other treatments being developed for the same indication.The results from th ...

On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L).These data were presented at the American Heart Association (AHA) Scientific Sessions.Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------| | £000s (except per share information) | Three months ended \nSeptember 30, 2024 \n£000s | Three months ended \nS ...

Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc (NASDAQ:SLN) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platform to produce short interfering RNAs (siRNAs) that degrade disease-related mRNA. It focuses especially on genes expressed in the liver, which is an ideal target due to its essential role in metabolism and regulating proteins, fats, and carbohydrates. Currently, SLNCF's main drug candida ...

andresr/E+ via Getty Images The last time I wrote about Silence Therapeutics plc (NASDAQ:SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article, I noted that the company had already released positive results using one of its small interfering RNA [siRNA] candidates, known as zerlasiran. This is for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]. ...

Exhibit 99.1 Condensed consolidated income statement (unaudited) | --- | --- | --- | --- | --- | |---------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------|--------------------------------------------------| | £000s (except per share information) | Three months ended \nJune 30, 2024 \n£000s | Three months ended \nJune 30, 2023 \n£000s | Six ...

Last month, the company announced positive data from the ongoing phase I repeat dose SANRECO study on its pipeline candidate, divesiran (SLN124) for treating patients with polycythemia vera. Treatment with divesiran was generally well-tolerated and eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing. This might have driven the share price rally. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) s ...

Risks To Business A third risk to consider would be regarding the partnership with AstraZeneca that had been done to advance siRNA drug candidate for the treatment of patients with cardiovascular, renal, metabolic and respiratory diseases. Thus far, Silence Therapeutics was able to receive $10 million from the collaboration agreement because of the nomination of one candidate. The ability to obtain additional milestone payments is going to depend upon whether other candidates are ultimately nominated. There ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Conference March 13, 2024 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Head of R&D Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Patrick Trucchio - H.C. Wainwright Keay Nakae - Chardan Research Operator Good day, and thank you for standing by. We ...